CITIC (00267): Citic Press Corporation (300788.SZ) reported a net profit attributable to the parent company of approximately 77.0585 million yuan in the first half of the year, a year-on-year decrease of 36.42%.
CITIC Limited (00267) announced the interim results of CITIC Publishing (300788.SZ) for 2026, with operating revenue of approximately 791 million yuan, a year-on-year decrease of 3.87%; net profit attributable to shareholders of the listed company was approximately 77.0585 million yuan, a year-on-year decrease of 36.42%; basic earnings per share were 0.41 yuan, and a cash dividend of 1.02 yuan (tax included) was distributed for every 10 shares.
CITIC (00267) announced that Citic Press Corporation (300788.SZ) recorded its mid-year performance for 2026, with operating revenue of approximately 791 million yuan, a year-on-year decrease of 3.87%; net profit attributable to shareholders of the listed company was approximately 77.0585 million yuan, a year-on-year decrease of 36.42%; basic earnings per share were 0.41 yuan, with a cash dividend of 1.02 yuan per 10 shares (tax included).
The announcement stated that the decline in performance was due to the high baseline data driven by the super bestseller series "Nezha: The Past of the Three Realms" from the same period last year, leading to a 13.64% year-on-year decrease in revenue from the book publishing and distribution business. During the reporting period, Citic Press Corporation elevated its IP operations business to the fourth major business segment alongside book publishing and distribution, digital intelligence services, and urban cultural space operations. Revenue from digital intelligence services and urban cultural space operations grew by 8.32% and 13.47%, respectively, while the IP operations business saw a year-on-year increase of 174.46%, achieving rapid growth.
Related Articles

SHUOAO INTL (02336) announced its interim results, with a profit attributable to shareholders of HKD 1.909 million, returning to profitability year-on-year.

CF PHARMTECH (02652): ICF001 expands its indications after obtaining implied approval for clinical trials from the National Medical Products Administration.

CICC (03908) issues 4.6 billion yuan perpetual subordinate bonds.
SHUOAO INTL (02336) announced its interim results, with a profit attributable to shareholders of HKD 1.909 million, returning to profitability year-on-year.

CF PHARMTECH (02652): ICF001 expands its indications after obtaining implied approval for clinical trials from the National Medical Products Administration.

CICC (03908) issues 4.6 billion yuan perpetual subordinate bonds.

RECOMMEND





